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Non-standard abbreviations 
ADCC Antibody-dependent cell-mediated cytotoxicity 
APCs Antigen presenting cells 
BCG Bacille Calmette-Guerin 
CHO Chinese Hamster Ovary 
Cys cysteine 
DAPI 4,6-diamidino-2-phenylindole 
DLS Dynamic Light Scattering 
ELISA Enzyme-linked immunosorbent assay 
HIV Human Immunodeficiency Virus 
IFN-γ Interferon gamma 
IL Interleukin 
MFI Mean fluorescent intensity 
MPL Monophosphoryl lipid A 
N. benthamiana Nicotiana benthamiana 
PBS Phosphate buffered saline 
PIGS Polymeric Immunoglobulin G scaffold 
poly(I:C) Polyriboinosinic-polyribocytidylic acid 
Pro proline 
RICs Recombinant immune complexes 
RNAi RNA interference 
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RUs Response Units 
SDS-PAGE Sodium dodecylsulphate-polyacrylamide gel electrophoresis 
SEC-UV Size Exclusion Chromatography-Ultra-Violet spectrophotometry 
Ser serine 
SPR Surface plasmon resonance 
TB Tuberculosis 
TB-PIGS Tuberculosis antigen 85B fused to PIGS 
Thr threonine 
TNF-α Tumour necrosis factor alpha 
TTFC Tetanus toxin fragment C 
μtp Mu immunoglobulin chain tail piece 
 
Abstract 
In this study, a strategy based on polymeric immunoglobulin G scaffolds (PIGS), was used to 
produce a vaccine candidate for Mycobacterium tuberculosis. A genetic fusion construct 
comprising genes encoding the mycobacterial Ag85B antigen, an immunoglobulin γ-chain 
fragment and the tailpiece from immunoglobulin μ chain was engineered. Expression was 
attempted in Chinese Hamster Ovary (CHO) cells and in Nicotiana benthamiana. The 
recombinant protein assembled into polymeric structures (TB-PIGS) in N. benthamiana, 
similar in size to polymeric IgM. These complexes were subsequently shown to bind to the 
complement protein C1q and FcγRs with increased affinity. Modification of the N-glycans 
linked to TB-PIGS by removal of xylose and fucose residues that are normally found in plant 
glycosylated proteins, also resulted in increased affinity for low affinity FcγRs. Immunisation 
studies in mice indicated that TB-PIGS are highly immunogenic with and without adjuvant. 
However, they did not improve protective efficacy in mice against challenge with M. 
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tuberculosis compared to conventional vaccination with BCG, suggesting that additional or 
alternative antigens may be needed to protect against this disease. Nevertheless, these results 
establish a novel platform for producing polymeric antigen-IgG γ-chain molecules with 
inherent functional characteristics that are desirable in vaccines.  
 
Introduction 
Vaccination against infectious disease has been one of the great medical success stories of the 
last century. However, there remain many diseases for which vaccines remain undeveloped, 
as well as diseases where better vaccines are urgently needed. Modern vaccine development 
also prioritises strategies to improve accessibility, availability and acceptability, which 
include cost, mode of administration and administration regime. 
 
Vaccines based on recombinant protein antigens are attractive for many reasons, but 
administration of antigen alone is rarely sufficient to stimulate a potent, long-lasting immune 
response. In almost all cases, an adjuvant is required to boost immunogenicity or to favour a 
specific kind of immune response. Adjuvant development is a major challenge for the vaccine 
industry (Reed et al. 2013). For this reason, antigens that have “self-adjuvanting” properties 
are of interest, as they would greatly simplify vaccine manufacture and development.  
 
In the early stages of a normal immune response, the formation of natural immune complexes 
is an important step for targeting antigen presenting cells (APCs), activation of the classical 
complement cascade and other immunoregulatory functions (Wen et al. 2016). An approach 
to produce recombinant monoclonal immune complexes has been described using plant 
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biotechnology, which results in the desired Fc effector functionality and proof of concept for 
enhanced immunogenicity was described for tetanus toxin (Chargelegue et al. 2005), Ebola 
virus glycoprotein (Phoolcharoen et al. 2011), Mycobacterium tuberculosis Ag85B (Pepponi 
et al. 2014) and a dengue vaccine candidate (Kim et al. 2015 ).    
 
An alternative approach to assembling and expressing recombinant immune complexes has 
recently been described, using a strategy involving a polymeric immunoglobulin G scaffold 
(Mekhaiel et al. 2011). Hexa-Fc fusion proteins were engineered using a variety of proteins 
of interest, fused to the Fc region of Human IgG1. The addition of the 18 amino acid tail 
piece from human IgM resulted in well-defined hexameric structures, which bound 
differently to complement, Fc Receptors and B-cells compared to their monomeric 
counterparts (Mekhaiel et al. 2011).  
 
In this study, we investigate the use of the polymeric immunoglobulin G scaffold to create a 
multivalent vaccine candidate (TB-PIGS) based on the Ag85B antigen of M. tuberculosis. 
Ag85B is the major component of the Ag85 complex, which in turn, is the major secreted 
component in mycobacterial culture fluids (Wiker & Harboe 1992). Early promising results 
with Ag85B led to its inclusion in the vaccine candidate rBCG30 as well as being fused to a 
plethora of other proteins such as ESAT-6 in subunit vaccine candidates (Horwitz et al. 1995; 
Horwitz et al. 2000) and it is still a priority candidate for current vaccine developers (Babaki 
et al. 2017).  
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We compare the expression of TB-PIGS incorporating mouse IgG2a and human IgG1 
sequences, and we also assess their expression in CHO cells and transient expression in 
Nicotiana benthamiana. We report characterisation of the assembly of the TB-PIGS, their 
size and in vitro functional properties. Finally, we describe the immunogenicity of TB-PIGS 
in a mouse model, as well as the response to challenge with M. tuberculosis. 
 
Results 
Design and expression of TB-PIGS in wild-type and transgenic ΔXF plants 
DNA sequences for murine (Mseγ2a) and human (Huγ1) heavy chain scaffolds were 
synthesised using commercial codon optimisation algorithms for plant and mammalian 
expression. The scaffolds contained the nucleotide sequence encoding the CH2 and CH3 
domains as well as the last 9-10 amino acid residues of the CH1 domain for either Mseγ2a or 
Huγ1 (Figure 1). For Huγ1 constructs, Cys
230
 was substituted to Ser in the hinge region, to 
prevent disulphide bond formation occurring, in the absence of light chain. The Ag85B 
sequence was incorporated at the 5’end of each scaffold sequence. 
 
The μtp from IgM was added to the C-terminus of the CH3 domain of the γ-chains and in both 
mouse and human versions, Pro
476
 was substituted to Thr to ensure that the terminal residues 
of the CH3 domain of the γ-chain are identical to those of the CH4 domain of the µ-chain. 
This had previously been suggested to help integrate the two immunoglobulin domains 
together and prevent disruption of IgM polymeric structural abilities (Smith et al. 1995). IgM 
predominantly forms hexameric molecules in the absence of J-chain and pentameric 
molecules in the presence of J-chain (Randall et al. 1992). Assembly of TB-PIGS into 
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monomeric (IgG-like) structures would result in molecular structures of approximate Mr 
120K. Subsequent hexameric assembly (as no J-chain will be present) would result in 
molecular structures of approximate Mr 720K (Figure 1).  
 
Initially, expression was attempted in mammalian CHO cells which were transfected with 
pEF-DEST51::TB-PIGS vectors, using both murine and human-based scaffolds. The 
transfected CHO cells were selected using blasticidin. Although CHO cell transfections were 
attempted repeatedly, no successful transfectants were recovered for TB-PIGS. Successful 
transfections were however recovered on each occasion for a control PIGS protein, 
comprising the immunoglobulin scaffold without antigen (Supplementary Figure S1).  
 
Two N. benthamiana plant lines were vacuum infiltrated with Agrobacteria containing 
pTRAk.2::TB-PIGS vectors, using both murine and human-based scaffolds. Wild-type N. 
benthamiana results in recombinant protein production with typical plant glycosylation, 
whereas a glyco-engineered N. benthamiana line in which xylosyl- and fucosyl-transferases 
were deleted, results in glycoproteins with glycans that are more similar to those commonly 
found in mammalian systems (Strasser et al. 2008). Five days post-infiltration, the leaves 
were harvested and soluble protein was extracted. Recombinant antibody molecules were 
purified by protein A affinity chromatography.  
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Expression and assembly of TB-PIGS 
Plant samples were analysed by SDS-PAGE and Western blotting using anti-serum specific 
for Ag85B, human γ1 or mouse γ2a immunoglobulin chains (Figure 2). Under non-reducing 
conditions, coomassie blue stained SDS-PAGE demonstrates three major protein groups for 
both Human TB-PIGS and Murine TB-PIGS (Figure 2A panels i-ii). There was a major band 
at approx. Mr ~120K (labelled M), which is the predicted size for the PIGS monomer (Figure 
1). Protein bands of higher Mr are also present (~250K and greater, labelled P), which are 
likely to represent polymeric structures. There are also major bands at Mr ~60K (labelled S) 
which may be single chain, unassembled fusion proteins, or degradation products. For 
comparison, commercial purified human IgG1, human IgM and murine IgG2a were also 
analysed on the same gels. Under reducing conditions, the human TB-PIGS sample resolved 
into a predominant band of approximate Mr ~60K, which is likely to represent unassembled 
single fusion proteins (Figure 2A panels iii-iv). A similar size band was observed for the 
murine TB-PIGS, but the predominant band was Mr ~100K, which may be a dimer. Some 
lower molecular bands were also evident, particularly in the case of the Human TB-PIGS, 
which are likely to represent truncated degradation products. For comparison, reduced 
samples of commercial purified human IgG1, human IgM and murine IgG2a were also run, 
demonstrating bands at the expected Mr for immunoglobulin heavy and light chains.  
 
The identity of the bands was supported by Western blotting using antigen and antibody-
specific antisera. Under non-reducing conditions, all the major protein bands in the human 
and murine TB-PIGS samples were detected using both anti-Ag85B and anti-
immunoglobulin heavy chain (anti-Human 1 or anti-Mouse 2a) antisera (Figure 2B panels 
i-iii).  Under reducing conditions, the major Mr ~60K was detected with both anti-Ag85B and 
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anti-immunoglobulin heavy chain antisera, but the lower Mr bands <37K were only detected 
by the anti-immunoglobulin heavy chain antisera (Figure 2B panels iv-vi).  
 
Similar results were obtained when the human and murine TB-PIGS were expressed in glyco-
engineered (ΔXF) N. benthamiana (data not shown). Successful glyco-engineering was 
confirmed by Western blotting using specific antisera to confirm the absence of xylose and 
fucose residues on recombinant proteins expressed in ΔXF plants (results not shown). 
 
Fully assembled hexameric TB-PIGS are very large proteins that would be difficult to 
visualise by SDS-PAGE. Two different systems were therefore utilised to demonstrate 
polymeric assembly of TB-PIGS more accurately; native PAGE (Figure 2C), and size 
exclusion chromatography-ultraviolet spectrophotometry (SEC-UV; Figure 2D).  
 
Native PAGE (Figure 2C) indicated that human TB-PIGS assembled into four major protein 
bands, that were consistent with polymers (800-1000K), dimers (two bands ~240-300K) and 
probably monomers (~140K). The murine TB-PIGS however appeared predominantly as a 
single band (~250K). Commercial human and murine IgM standards were run in parallel. 
Under, SEC-UV (Figure 2D), the murine TB-PIGS (expressed in ΔXF plants) resolved into 
two peaks (retention time 19.2 and 20.5 mins), which are consistent with results expected for 
dimer/monomer and a single chain. Four species were observed in the human TB-PIGS:ΔXF 
sample; with retention times consistent with those expected for polymers, dimers, monomers 
and single chain. The molecular weights of TB-PIGS species were determined by comparison 
with retention times for proteins of known molecular weight within the BioRad standards 
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sample (from left to right - Vitamin B12 (1.35K), myoglobin (17K), ovalbumin (44K), γ-
globulin (158K) and thyroglobulin (670K)). Yield estimations are provided in supplementary 
table S1. 
 
Functional characterisation of TB-PIGS 
To assess functionality of TB-PIGS, their binding to C1q (the first component of the classical 
complement pathway) was determined by ELISA (Figure 3A). Both the human and murine 
TB-PIGS, produced in wild-type and glyco-engineered ΔXF plants, bound to C1q in a 
concentration dependent manner. WT crude plant extract, Ag85B, MseIgG2a and HuIgG1 
(all used as negative controls) only resulted in minimal or no binding to C1q. In contrast, 
ICMs (immune complex mimetics positive control; consisting of murine IgG1 monoclonal 
antibody bound to polymeric M. tb antigen Acr in an immune complex), bound to C1q.   
 
Surface plasmon resonance (SPR) was used to determine affinity and kinetics of binding 
between human TB-PIGS and the high affinity receptor CD64 (FcγRI) or low affinity 
receptors CD16a and CD32a (FcγRIIIa and FcγRIIIa) (Supplementary Figure S2 and Table 
S2). This experiment was to determine the individual interaction of FcγR with a single ‘arm’ 
of the polymeric TB-PIGS, to determine that the FcγR-binding site on the engineered IgG-
like structure retains its proper activity. Human TB-PIGS produced in ΔXF plants had high 
affinity binding to CD64 (0.41nM) which was similar to the affinity of human IgG1 with the 
same receptor (0.27nM) as expected. Human TB-PIGS expressed with normal plant 
glycosylation had approximately 10-fold lower affinity binding to CD64. The affinity of 
human TB-PIGS to CD16a was superior to human IgG1 as expected. In particular, the KD for 
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glyco-engineered human TB-PIGS was 19.7 nM compared with the KD for human IgG1 of 
673 nM. The binding affinities of human IgG1 and human TB-PIGS expressed in WT or 
ΔXF plants were similar, and in the micromolar range. 
 
SPR was also used to demonstrate differences in avidity between glycoengineered human 
TB-PIGS:ΔXF with low affinity FcγRs, compared to monomeric (commercial) HuIgG1. The 
experimental set-up involved tethering multiple FcγRs to the chip surface allowing polymeric 
TB-PIGS to bind to multiple receptors simultaneously, allowing avidity measurements. 
Although avidity cannot be quantified accurately in this assay, the differences between TB-
PIGS:ΔXF and HuIgG1 are evident from the dissociation curves (Figure 3B and C). For both 
CD32a and CD16a, the dissociation of HuIgG1 is rapid and almost complete within seconds. 
In contrast, the TB-PIGS:ΔXF dissociate more slowly, particularly from CD32a.     
 
Binding of TB-PIGS to monocyte cell lines 
SPR demonstrated binding of TB-PIGS to soluble FcγRs. This activity was next confirmed ex 
vivo by demonstrating binding to human TB-PIGS by THP-1 cells (a human monocyte cell 
line expressing FcγRs on their cellular surface) by both flow cytometry (Supplementary 
Figure S3) and confocal microscopy (Figure 4).  
 
THP-1 cells were pre-treated with commercial “Fc block”, to block binding to CD64, then 
incubated with either medium, a rabbit IgG antiserum, or HuIgG1 as controls, and human 
TB-PIGS produced in ΔXF plants as indicated. THP-1 nuclear staining was performed with 
DAPI (blue- first column). Detection of antibody or TB-PIGS binding to the cells was with 
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either rabbit α-Ag85B antiserum, followed by a goat α-Rabbit Ig-Alexa Fluor488 antiserum 
(green– second column), or sheep α-HuIgG1 followed by donkey α-sheep IgG-Alexa 
Fluor633 (magenta– third column). Superimposed images are shown in the fourth column. 
 
After blocking CD64, HuIgG1 did not bind to the low affinity FcγRs as expected (Figure 4 
row 3). Human TB-PIGS:ΔXF binding to THP-1 was detected using both α-Ag85B and α-
HuIgG1 antisera (Figure 4 row 4). This result was supported by the flow cytometry analysis, 
which demonstrated very low level of fluorescence for HuIgG1 (Supplementary Figure S3), 
increased fluorescent signal for human TB-PIGS:ΔXF, consistent with the signal for heat 
aggregated IgG1 which was used as the positive control.  
 
Similar results were observed for binding of murine TB-PIGS to FcγRs on the surface of 
J774 cells (a mouse monocyte/macrophage cell line), although in this case, high affinity 
receptors were not blocked so binding to these receptors was observed using MseIgG2a 
control (Supplementary Figure S5).Use of phalloidin and DAPI staining for cytoplasm and 
nuclei, respectively, indicated that TB-PIGS bind to receptors on the surface of the cell and 
may be taken-up by the cell (Supplementary Figures S4).  
 
In vivo immunogenicity and protective efficacy elicited by TB-PIGS 
BALB/c mice were immunised with murine TB-PIGS, produced in both wild-type and ΔXF 
N. benthamiana, with and without adjuvant. TB-PIGS were highly immunogenic, but plant-
produced Ag85B alone was not (Figure 5 A-C). An Ag85B specific antibody response was 
observed in all animals immunised with Murine TB-PIGS (Figure 5A). Murine TB-PIGS 
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alone in particular induced a strong IgG1 (Th2-type) response but this shifted to a mixed 
Th1/Th2 response with the addition of MPL adjuvant, as indicated by production of α-
Ag85B-specific IgG2a antibodies. 
 
Ag85B specific T-cell proliferative responses were also observed following in vitro 
stimulation of splenocyte cultures with Ag85B. Figures 5B and 5C show the analysis of 
specific poly-functional CD4
+
 and CD8
+
 cells respectively. Surprisingly, the PBS control 
group was found to have some specific CD4
+
 T-cell response. However, TB-PIGS from ΔXF 
N. benthamiana but not WT plants induced a higher proportion of triple positive cells 
compared to either PBS or BCG groups. Addition of MPL adjuvant increased the proportion 
of double positive cells but abolished the triple positive cells, similar to antigen stimulation 
alone. In the CD8
+
 T-cell compartment, the striking finding was that TB-PIGS from ΔXF N. 
benthamiana induced exclusively triple positive cells and was superior to all other groups, 
including when combined with the MPL adjuvant. Overall, the data showed that TB-PIGS 
from ΔXF N. benthamiana are highly potent in inducing triple positive CD4+ and CD8+ T-
cells and that this was largely reversed by the addition of MPL adjuvant. 
 
Finally, the potential protective efficacy of TB-PIGS was assessed following intranasal 
aerosol challenge with M. tuberculosis. By assessment of recoverable bacterial counts from 
lungs and spleens, no improvement in protective efficacy compared to PBS immunised mice 
was observed (Figure 5 D). 
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To test the human TB-PIGS, a similar study was performed using transgenic CD64 (human 
FcγRI) mice. Immunisation was with human TB-PIGS, produced in ΔXF N. benthamiana, 
with and without BCG priming. Two adjuvants were tested, MPL and poly(I:C).   
 
As with the Murine TB-PIGS, an Ag85B specific antibody response was elicited in all 
animals immunised with Human TB-PIGS (Figure 6A). Similar mixed IgG1/IgG2a responses 
were seen in the three groups, all of which received an adjuvant. BCG priming did not have a 
significant effect. 
 
Analysis of splenocyte cytokine responses (Figure 6B) also suggests a mixed Th1/Th2 
response. All groups except PBS + MPL control group, resulted in high levels of IFN-γ. If 
mice did not receive BCG, statistically lower levels of IL-2 were produced. Poly(I:C), with or 
without BCG priming, resulted in increased levels of TNF-α, compared to control mice or 
those receiving MPL adjuvant. However, the most balanced cytokine response appeared in 
the group that was primed with BCG and received Human TB-PIGS:ΔXF + MPL adjuvant. 
Furthermore, analysis of polyfunctional T-cells (Figure 7A) indicated that this was the only 
group in which CD4
+
 quadruple cytokine producing T-cells were elicited. A high proportion 
of triple (IFN-γ, IL-2 and TNF-α) and double (IFN-γ and IL-17) cytokine producing 
CD4
+
cells was also observed in this group, as well as in the BCG primed group that received 
human TB-PIGS:ΔXF with poly(I:C) adjuvant. CD8+ cells were largely restricted to single 
cytokine producers in all groups, except for this latter group that was primed with BCG and 
boosted with human TB-PIGS:ΔXF + poly(I:C) adjuvant. Here there was a significant 
proportion of double and triple cytokine producing T-cells (Figure 7B). In both cases, mice 
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primed with BCG and boosted with human TB-PIGS resulted in greater numbers of α-
Ag85B-specific T-cells compared to control groups.  
 
Finally, none of the vaccine candidate groups resulted in a statistical reduction in bacterial 
load in the lungs, compared to mice immunised with BCG (Figure 7C left). However, mice 
primed with BCG and boosted with human TB-PIGS:ΔXF + poly(I:C) adjuvant resulted in a 
statistically significant reduction in bacterial load in the spleens, compared to mice 
immunised with BCG (Figure 7C right). 
 
Discussion 
Tuberculosis is a major global health problem, due to limitations of the BCG vaccine, the rise 
of multidrug resistant and extensively drug resistant TB cases, as well as the increased 
prevalence of immunocompromised people (Cayabyab et al. 2012). A considerable effort is 
therefore being made to develop a new TB vaccine to either replace or boost BCG-
immunisation. Ag85B is an established vaccine candidate and was used in this study as a 
model antigen to assess a novel molecular platform for vaccine design. PIGS is an attractive 
platform because it is designed to present multiple copies of antigen whilst also directly 
targeting APCs through Fc receptors to enhance antigen uptake and presentation.  
 
Two expression systems were tested for production of the TB-PIGS. CHO cells were selected 
because they are currently the industry standard for recombinant immunoglobulin 
pharmaceuticals, and transient expression in Nicotiana benthamiana, an emerging plant 
expression system with significant potential advantages in relation to pharmaceuticals that are 
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urgently needed in low and middle income countries (Chen & Davis 2016).  Nicotiana plants 
are well documented to express antibodies and antibody complexes extremely efficiently and 
accurately (Chargelegue et al. 2005; Hiatt et al. 1989; Ma et al. 1995; Teh et al. 2014).  
Unexpectedly, we were unable to express any TB-PIGS in CHO cells. The PIG scaffold 
alone, lacking Ag85B, was expressed successfully in CHO cells, suggesting a protein specific 
issue, such as toxicity of the antigen or the overall size of TB-PIGS.  
 
We generated a murine 2a scaffold first because we planned to perform pilot in vivo testing 
in mice, but we also designed and expressed a human γ1 in anticipation of developing a 
vaccine product. Both could be expressed in Nicotiana benthamiana although differences in 
polymerisation states were observed. Native PAGE indicated that the human scaffold resulted 
in a greater proportion of polymers (~35-60%) compared to monomers (~1-10%), whereas 
Mseγ2a scaffolds resulted in predominantly monomers (~45-60%) compared to polymers (~5-
20%). This finding was partly corroborated by SEC-UV spectrophotometry. Mekhaiel et al. 
also found that Human IgG1-based hexa-Fc constructs could form hexameric structures, yet, 
their Mouse IgG2a-based constructs did not form anything larger than a dimer (Mekhaiel et 
al. 2011). The reason for these differences is unknown. Further improvement in polymer 
yields may require additional mutations, such as the L309C mutation in human IgG1 heavy 
chain, which has been indicated to increase yields of polymers, as it is homologous to Cys414 
in IgM, which has been shown to have a role in inter-heavy chain disulphide bonds (Mekhaiel 
et al. 2011, Sorensen et al. 1999, Yoo et al. 1999). However, this mutation does not always 
improve polymer yields (Teye et al. 2017). 
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The PIG scaffold is designed to mimic polymeric IgM and the Fc mediated properties of that 
molecule. Functional assessment of the TB-PIGS included assays to demonstrate binding to 
complement and Fc receptors. The classical complement pathway is normally activated by 
polymeric antigen-bound IgG or IgM binding to C1q, leading to activation of the enzyme 
cascade. IgG normally exists in a monomeric state, in which the C1q binding site is 
accessible but the affinity is too low to bind and activate C1q (Diebolder et al. 2014). IgG 
needs to polymerise to bind C1q with high avidity (Diebolder et al. 2014). The demonstration 
that TB-PIGS could bind to C1q was therefore an indication of their polymeric status. These 
results support similar findings by Smith et al. but contrast with Mekhaiel et al., who showed 
that hexa-Fc fusion molecules bound C1q poorly compared to dimers and monomers 
(Mekhaiel et al. 2011; Smith & Morrison 1994; Smith et al. 1995). Mekhaiel et al., also 
showed that the interaction of their hexa-Fc molecules with FcγRs was dependent on the 
fusion partner. They hypothesised that these results may be due to steric hindrance, caused by 
the antigen blocking the C1q or FcR binding site located in or near the hinge region. 
Therefore, in our constructs, we included the last 9-10 amino acid residues of the CH1 
domain, corresponding to a -strand, to add molecular flexibility and to avoid any potential 
steric interference.  
 
The only known difference between antibodies expressed in plants and those expressed by 
mammalian cells is in N-glycosylation. Although the initial steps of N-glycosylation and N-
glycan processing are highly conserved between plants and mammals, subsequent N-glycan 
maturation differs in plants resulting in complex N-glycans with β1,2-linked xylose, core 
α1,3-linked fucose and Lewis A-type structures that are not found in mammalian antibody 
glycosylation (Cabanes-Macheteau et al. 1999; Strasser 2016).  Glycosylation is known to 
impact molecular interactions of IgG (Hayes et al. 2014; Hodoniczky et al. 2005; Shields et 
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al. 2002; Zhou et al. 2008). In particular, N-linked glycan structures present at Asn 297 in 
IgG, can modulate FcγR binding, which affects the immune response induced (Mimura et al. 
2001). For example, removal of fucose has been shown to improve binding of antibody to 
FcγRIIIa and results in enhanced antibody dependent cell-mediated cytotoxicity (ADCC) 
(Ferrara et al. 2011; Shields et al. 2001), so here we made use of a glyco-engineered line of 
N. benthamiana (Strasser et al. 2008) in which the endogenous α1,3-fucosyltransferase was 
silenced. Our results showed that the use of the glyco-engineered Nicotiana benthamiana 
host had no impact on expression or assembly of TB-PIGS. There was no functional loss 
associated with TB-PIGS expressed in glyco-engineered plants, for example they bound 
equally well to C1q, but there was an important enhancement of binding affinity to CD64 and 
CD16a as predicted from previous reports (Hiatt et al. 2014). 
 
Physiologically, IgG binds with high affinity to FcγRI/CD64,  whereas immune complexes 
bind preferentially to low affinity receptors (FcγRII/CD32 and FcγRIII/CD16) (Klaassen et 
al. 1988; Lux et al. 2013; White et al. 2001). In our studies, the human TB-PIGS bound with 
high affinity to FcγRI/CD64 and the glyco-engineered human TB-PIGS bound with enhanced 
affinity to FcγRII/CD32a and FcγRIII/CD16a. Potentially, this indicates that like naturally 
formed immune complexes, human TB-PIGS could interact efficiently with immature 
dendritic cells (DCs) (reviewed in Platzer et al. 2014), resulting in endocytosis and leading to 
maturation and migration of the DCs to secondary lymphoid organs, where cytokines are 
produced that activate specific naïve T-cells. M. tuberculosis has evolved to evade the human 
immune system, for example, by ‘hiding’ inside macrophages. This indicates that a vaccine 
candidate should elicit T-cell responses (reviewed in Scriba et al. 2017). Recently, B cells 
and antibodies have also been indicated to be important in controlling M. tuberculosis disease 
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(reviewed in du Plessis et al. 2016). Moreover, phagocytosis and ADCC may be impaired 
during active tuberculosis disease, possibly due to a decrease in antibody avidity (Arias-
bouda et al. 2003; Perley et al. 2014) and/or downregulation of Fc receptor expression 
(Jacobsen et al. 2007; Laux da Costa et al. 2015; J. Maertzdorf et al. 2011; Jeroen Maertzdorf 
et al. 2011). Therefore, improvement of antibody avidity and Fc receptor engagement may be 
a crucial area of research for protection against M. tuberculosis.  
 
Mouse TB-PIGS affinities for mouse FcγRs were inconsistent, but generally lower than 
observed for human TB-PIGS against human FcγRs (data not shown). These differences may 
be due to less efficient polymerisation of the PIG scaffold. In addition, murine FcγR have 
been less well studied than their human counterpart, so there may be unrecognised biological 
differences The classification of murine FcγR homologs is based on amino acid similarity, 
rather than ligand binding or cellular expression (Bruhns 2015), for example, mouse FcγRIV 
has been suggested to be the functional equivalent of both human FcγRI and human FcγRIIIa 
(Mechetina et al. 2002; Nimmerjahn et al. 2005). Investigation of half-lives for murine TB-
PIGS with mouse FcγRI were inconclusive, but suggested that the dissociation is much faster 
than for human reagents (data not shown), which is a consideration in the analysis of in vivo 
results. 
 
In vivo murine and human TB-PIGS were tested in conventional and human CD64 transgenic 
BALB/c mice respectively. Murine TB-PIGS (produced in wild-type and ΔXF plants) 
generated humoral and cellular immunity with and without adjuvant, but failed to reduce the 
bacterial load in challenged mice, compared to BCG immunised mice. Murine TB-PIGS:ΔXF 
did however, result in a greater percentage of triple-cytokine producing CD4
+
 and CD8
+
 cells, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
which have been suggested to be important in protecting against M. tuberculosis infection. In 
the second in vivo study, human TB-PIGS were used to immunise transgenic CD64 mice with 
and without BCG priming. The best IgG2a-specific response with quadruple-cytokine 
producing CD4
+
 cells was generated by mice primed with BCG and boosted with human TB-
PIGS:ΔXF + MPL adjuvant. In contrast, the greatest proportion of triple-cytokine producing 
CD8
+
 cells was found for mice immunised with BCG and boosted with human TB-
PIGS:ΔXF + poly(I:C). CFU counts indicated this was the most promising vaccine candidate 
as there was a statistically significant reduction in bacterial burden in spleens of challenged 
mice compared to BCG immunised mice, suggesting that this vaccine candidate could impair 
MTB dissemination in vivo. However, only a marginal reduction was observed in lungs of 
challenged mice, which is important as the lungs are the primary site of entry for the 
pathogen.   
 
Tuberculosis poses some fundamental challenges in the evaluation of vaccine candidates. 
There are questions about the predictive value of animal models for human disease, and there 
is a lack of correlates of vaccine-induced protection (Karp et al. 2015).  In addition to testing 
humoral and cellular immunity, we tested protection against mycobacterial challenge, but this 
is a demanding end-point for in vivo assessment of TB-PIGS as a vaccine candidate for a 
number of reasons. Importantly, Ag85B, although extensively studied, has not yet been 
demonstrated to provide consistent protection against infection. So its role in this study was 
as a model immunogen, rather than as a confirmed vaccine protein. Secondly, one of the main 
attractions of the PIG scaffold is its potential for targeting Fc receptors on APCs. As noted 
above, the biology of murine Fc receptors in relation to their human counterparts still needs 
clarification, and as our results suggested less polymerisation for murine TB-PIGS and 
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diminished binding affinity of murine TB-PIGS to murine FcRs compared with human TB-
PIGS to human FcRs, the murine model may not be optimal for protection studies. 
Furthermore, although we were able to test the human TB-PIGS in human CD64 transgenic 
mice, the animals were not transgenic for low affinity FcRs such as CD16a, which are 
known to play an important role in ADCC (Gupta et al. 2005).   
 
In this study, we have demonstrated the feasibility of polymeric IgG scaffolds as a vaccine 
platform. We illustrated expression, assembly and purification from Nicotiana benthamiana, 
and demonstrated in vitro and in vivo functional characteristics based on our hypothesis that 
PIGS would promote enhanced antigen presentation to the immune system. It builds on a 
parallel project using a dengue vaccine candidate (Kim et al. 2017 and Kim et al. 2018)  and 
demonstrates the generic potential of this platform to be used for vaccine candidates against a 
range of infectious diseases. Further work is now needed to optimise the formation of 
polymers, to enhance their stability and to maximise yields in the plant expression system in 
order to advance to safety and immunisation studies in humans. 
 
Experimental Procedures 
Construction of TB-PIGS vectors 
GeneArt synthesised four codon optimised constructs in pMA-T vector. Two genes were 
codon optimised for N. tabacum (human PIGS and murine PIGS) and the other two for H. 
sapiens (human PIGS
H
 and murine PIGS
H
). The PIGS sequence included leader sequence, 
truncated γ-chain (derived from either human IgGγ1 or mouse IgGγ2a) and μtp from IgM, all 
flanked by NcoI and XbaI restriction sites as well as attB gateway cloning sites. 
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Primer pairs containing BsaI restriction sites: 5’-
cagagcggtctcgatgcgaggtgttctctcgtcctggtttgcct-3’ and 5’-
tgttcaggtctcaaagcacctgctcccaaagaagattgaag-3’ were designed to amplify N-terminally 
truncated Ag85B (signal peptide removed) DNA fragment from pGEM::Ag85B-ESAT6 
construct (Dedieu et al. 2010) into pMA-T plasmid containing PIGS sequence by PCR in 
order to create pMA-T::human TB-PIGS and pMA-T::murine TB-PIGS. 
 
AttB1 and attB2 gateway cloning sites were used to clone Ag85B-human PIGS and Ag85B-
murine PIGS into pDONR-Zeo, using the BP Clonase II enzyme protocol (Invitrogen). The 
flanking NcoI and XbaI sites were used to clone the desired genes into pTRAk.2 (plant 
expression destination vector; van Dolleweerd et al. 2014; Sack et al. 2007) using T4 DNA 
Ligase (NEB).  
 
Expression of TB-PIGS and Ag85B in plants 
E. coli DH5α cells (Invitrogen) were transformed to amplify the plasmid, prior to 
electroporation of A. tumefaciens (strain GV3101::pMP90RK). A 400 ml A. tumefaciens 
culture was grown, centrifuged at 4,000 rpm for 20 minutes, and the pellet re-suspended in 
plant infiltration buffer (10 mM MES, 10 mM MgCl2 and 100 μg/ml acetosyringone at pH 
5.6) to an OD600 of 0.25. 6-8 week old N. benthamiana plants were immersed in A. 
tumefaciens solution inside a vacuum chamber with a vacuum pressure of <100 mbar for ~2 
minutes. After infiltration, the plants were maintained at 26ºC for ~5-6 days prior to leaf 
harvest for recombinant protein analysis. 
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Purification and characterisation of TB-PIGS from plants 
Whole leaves were frozen in liquid nitrogen and PBS (pH 7.0) was used as extraction buffer. 
A blender was used to homogenise the leaf material and then passed through miracloth 
(Merck) prior to centrifugation at 17,000g for 30 minutes. The supernatant was syringed 
through a 0.22 μm filter before being purified on protein-A-sepharose (SIGMA), except 
Ag85B which was purified on a nickel (II) affinity column. 
 
Eluted fractions were pooled, concentrated using Amicon Ultra-4 centrifugal filter devices 
and dialysed to exchange buffer for PBS (pH 7.0). The integrity of the proteins was 
determined by SDS-PAGE on NuPAGE 4-12% Bis-Tris gels (Novex), both non-reducing and 
reducing (10% β-mercaptoethanol), and the gels were stained with Coomassie Instant Blue 
stain (Expedeon). Additionally, NativePAGE 3-12% Bis-Tris gels (Novex) were utilised with 
NativeMark Unstained Protein Standard as per manufacturer’s protocol. ImageJ software was 
used to analyse the intensity of bands within each lane of the gel. A chromatogram was 
plotted and integration of the area under the curve used to determine a value for the percent 
of each species present. 
 
Proteins were also separated on a high performance SEC Yarra 300x7.8 column utilised on a 
HPLC LC2010A machine with PBS (pH 7.0) as buffer. Eluted fractions were compared 
against known high molecular weight standards (BioRad).  
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C1q binding ELISA 
Microtiter wells were coated with 5 μg/ml of human C1q (Merck Calbiochem) in PBS (pH 
7.0) and incubated at room temperature for two hours prior to blocking with 5% skimmed 
milk for 2 hours. The purified proteins, in PBS, were added to wells at a starting 
concentration of 100 μg/ml and in 5-fold dilutions in blocking buffer. Plates were incubated 
at room temperature for 2 hours before being washed with dH2O + 0.1% Tween20. Plates 
were incubated with detection antiserum (α-Hu IgGγ1-HRP, α-Mse IgGγ1-HRP, or α-Mse 
IgGγ2a-HRP), in blocking buffer, for 2 hours. Finally, plates were washed with dH2O + 0.1% 
Tween20 before being developed with 50 μl of HRP substrate in buffer (Sigmafast OPD 
tablet and Sigmafast buffer with urea H2O2 tablet in 20 ml dH2O). Absorbance was measured 
at 450nm (Tecan Infinite F200 PRO).  
 
Surface plasmon resonance  
SPR experiments were performed using the Biacore X100 instrument (GE Healthcare). Filter-
sterilised HBS-EP
+
 buffer was used as running buffer and dilution buffer. For determining 
affinity values; flow cells of CM5 sensor chips were coupled with recombinant protein A 
(SIGMA) using amine-coupled chemistry as described by the manufacturer. TB-PIGS were 
captured onto the surface of the chip. For analyte HuCD64 or MseCD64 (R&D systems) a 
flow rate of 40 μl/min, a contact time of 135 seconds, dissociation time of 600 seconds and 
regeneration buffer of 100 mM glycine (pH 1.5) was used. For analyte HuCD32a and 
HuCD16a (R&D systems) a flow rate of 40 μl/min, a contact time of 90 seconds, dissociation 
time of 300 seconds and regeneration buffer of 100 mM glycine (pH 1.5) was used. In all 
experiments, data were zero adjusted and evaluated using Biacore x100 software. For 
determining avidity; a His capture kit (GE Healthcare) was used to bind anti-histidine 
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antibody to the surface of a CM5 chip using amine-coupled chemistry. HuCD32a or 
HuCD16a were captured onto the surface of the chip. For analyte TB-PIGS a flow rate of 35 
μl/min, a contact time of 90 seconds, a dissociation time of 300 seconds and His capture kit 
regeneration buffer was used.  
 
Confocal Microscopy  
If Human FcR block (BD Pharmingen) was utilised, cells were incubated with 2.5 µg per 1 x 
10
6
 cells for 20 minutes at room temperature before addition of 25 µg of PIGS or control 
protein (HuIgG1 or MseIgG2a). Cells were incubated at room temperature for 2 hours before 
supernatant was discarded. Cells were washed with PBS before addition of 150 µl blocking 
buffer (PBS + 2% FBS + 1% BSA + 0.2% Triton X-100 + 0.05% Tween20) per well. The 
plate was incubated at room temperature for 1 hour before washing with PBS and fixing cells 
with 4% para-formaldehyde (SIGMA) for 20 minutes. Cells were washed with PBS + 7% 
glycine and permeabilised with 0.1% Triton X-100 for 5 minutes. Again, cells were washed 
with PBS before addition of primary antibodies (sheep α-HuIgG (TBS), sheep α-MseIgG 
(TBS), rabbit α-Ag85B (Abcam) or phalloidin-Alexa488 (LifeTechnologies)) in blocking 
buffer. Plates were incubated for 1 hour at room temperature, in the dark. Cells were washed 
with PBS and then secondary antibodies (donkey α-sheep IgG-AlexaFluor633 (Life 
Technologies) or goat α-rabbit IgG-AlexaFluor488 (Abcam)), in blocking buffer, was added 
for 1 hour, in the dark. Finally, cells were washed with IF wash (PBS + 0.2% Triton X-100 + 
0.05% Tween20), before DAPI was added for 15 seconds, washed twice more with IF wash 
and then addition of 200 µl PBS and stored at 4°C in the dark until imaging using a Zeiss 
Confocal LSM 510 and analysis using ImageJ software. 
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In vivo immunisation of mice 
All animals were housed in the Biological Research Facilities (BRF) at St. George’s, 
University of London, under Home Office regulations. Six to eight-week old female BALB/c 
mice purchased from Charles River/Harlan were used in all experiments with murine TB-
PIGS and were maintained under specific pathogen free conditions. Previously determined 
positive human CD64 mice were used to breed off-spring and tail-bleeds were screened by 
PCR to identify positive human CD64 transgenic mice. Infected animals were housed in 
cages contained within purpose-built plastic isolators under negative pressure, in a 
containment level 3 facility.  
 
Mice were immunised with TB-PIGS at 25 μg/dose administered subcutaneously (s.c.) or 
intranasally (i.n.) at 3 week intervals on three separate occasions, either alone or suspended 
with 20% v/v MPL (SIGMA) or poly(I:C) adjuvant (Invivo Gen). BCG priming was 
performed 9 weeks before first boost, by immunising mice with 2x10
6
 CFU/dose (BCG-
Pasteur).  
 
3 mice per vaccine group were culled 3-4 weeks after final immunisation. Mice were 
anaesthetised under isoflurane and cardiac puncture performed to collect blood. Spleens were 
removed into 5 ml R10 media. Blood was placed into a 37°C incubator for 30 minutes, then 
at 4°C for 2 hours, centrifuged at 13,000 rpm for 15 minutes and serum collected and stored 
at -20°C. Spleens for each group were combined and macerated through a 70 µm cell strainer 
using a sterile syringe plunger and washed into a petri-dish with 25ml of R10 media. Cells 
were centrifuged at 400g for 10 minutes and re-suspended in 5 ml/spleen ACK red blood cell 
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lysis buffer (ThermoFisher Scientific) for 7 minutes. 40 ml of R10 media was added to halt 
the reaction, cells were centrifuged for 10 minutes at 400g, washed with 20 ml R10 buffer, 
centrifuged 10 minutes at 400g and pellet re-suspended in 10 ml R10 buffer. Viable cells 
were counted using 0.4% trypan blue dye, counting slides and BioRad TC20 automated cell 
counter. 
 
Humoral Responses 
Microtiter wells were coated for two hours at 37°C with 10 μg/ml of N. benthamiana 
produced Ag85B protein in PBS (pH 7.0). Plates were washed with dH2O before being 
blocked for 1 hour, at 37°C, with PBS + 5% BSA. Plates were washed with dH2O. The 
mouse serum was added to wells (1:100) and a 3-fold serial dilution in blocking buffer. Plates 
were incubated at 37°C for 2 hours before being washed again with dH2O. Plates were 
incubated with secondary antibody (α-Mse IgG-HRP (TBS), α-Mse γ1-HRP (Abcam) or α-
Mse γ2a-HRP (STAR)), in blocking buffer, for 1 hour at 37°C. Finally, plates were washed 
with dH2O before being developed with 50 μl of HRP substrate in buffer (Sigmafast OPD 
tablet and Sigmafast buffer with urea H2O2 tablet in 20 ml dH2O) and the reaction stopped 
with 25 µl 2M H2SO4. Absorbance was measured at 450 nm (Tecan infinite F200 PRO). 
 
Cytokine responses 
Splenocytes were seeded at a concentration of 5 x 10
5
/ml per well in a 96-well U-bottomed 
plate (Corning). Cells were stimulated with 10 μg/ml of N. benthamiana produced Ag85B or 
5 μg/ml concanavalin A (ConA; SIGMA) as a positive control or R10 media as a negative 
control. Plates were incubated at 37°C, 5% CO2 and 90% humidity for 72 hours and 
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supernatants were harvested for cytokine ELISAs. Cytokine ELISAs were performed as per 
manufacturer’s instructions (eBiosciences). eBiosciences Mouse Th1/Th2 ELISA Ready-
SET-Go! kit detected IFN-γ, IL-2 and IL10. Mouse TNFα ELISA Ready-SET-Go! kit 
detected TNFα. 
 
Polyfunctional T-cell analysis 
Splenocytes were seeded at a concentration of 1.5 x 10
6
/ml per well in a 96-well V-bottomed 
plate. Cells were stimulated with R10 media containing 100 µg/ml of Brefeldin A (SIGMA) 
and 5 µg/ml of N. benthamiana produced Ag85B or 100 µg/ml Brefeldin A, 4 µg/ml Phorbol 
Myristate Acetate (PMA; SIGMA) and 20 µg/ml ionomycin calcium salt (SIGMA) as a 
positive control or 100 µg/ml Brefeldin A as a negative control. Plates were incubated at 
37°C, 5% CO2 and 90% humidity for 4 hours. Plates were centrifuged at 400g for 5 minutes 
at 4°C, and supernatant discarded. All cells (except two wells which were left as negative 
controls) were stained with viability dye eFluor 780 (1:2000; eBioscience) in PBS for 30 
minutes at 4°C, in the dark. Plates were washed with 200 µl PBS, centrifuged at 400g for 5 
minutes, and supernatant discarded. 100 µl Cytofix (BD) was added to each cell pellet and 
incubated at 4°C for 30 minutes, in the dark. The plates were washed with 200 µl FACS 
buffer, centrifuged at 400g for 5 minutes, and supernatants discarded. Pellets were re-
suspended in 200 µl FACS buffer and stored at 4°C, in the dark, overnight. 
 
The plates were centrifuged at 400g for 5 minutes and supernatants were discarded. 200 µl 
Permeabilisation Buffer (PBS + 0.5% BSA + 0.1% sodium azide + 0.5% saponin) was added 
to each well, centrifuged at 400g for 5 minutes and supernatant discarded. 25 µl of staining 
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cocktail (eFluor 780, α-TNF-α-APC, α-IL2-PE, α-IL17-Cy7, α-IFN-γ-PE-Dazzle, α-CD3-
FITC, α-CD4-PerCP-Cy5.5, and α-CD8-AlexaFluor700) was added to each pellet and 
incubated for 45 minutes at 4°C, in the dark. Fluorescence Minus One (FMO) stains were 
prepared as necessary and added to appropriate wells for 45 minutes at 4°C, in the dark. 
Similarly, Ultra compensation beads (eBiosciences) were stained for 45 minutes at 4°C in the 
dark and used for compensation. Cells were washed in 200 µl Permeabilisation buffer, 
centrifuged at 400g for 5 minutes, and supernatants discarded. Cells were washed in 200 µl 
FACS buffer, centrifuged at 400g for 5 minutes, and supernatants discarded. Finally, cells 
were re-suspended in 200 µl FACS buffer and stored at 4°C until acquisition on the flow 
cytometer (LSRII; BD). Analysis performed using FlowJo version 10. 
 
M. tuberculosis challenge 
Mice were transferred to Category III facilities and infected with aerosolised 200-500 CFU 
M. tuberculosis H37Rv for 10 minutes using a Biaera machine with Aero MP software 
(Management Platform) with nose-only chambers. They were culled 3 weeks post-challenge. 
Lungs and spleens were removed and homogenised in 5 ml of dH2O + 0.1% Triton X-100 
using a Seward 80 stomacher and serially diluted in dH2O + 0.1% Triton X-100 (1:5, 1:25 
and 1:125 for lungs and 1:5, 1:25 and 1:75 for spleens), 30 μl of each dilution was plated in 
duplicate onto 7H11 agar plates. CFUs were counted 3 weeks later. Due to limits of detection 
a log 2.2 value was attributed to spleen plates where no colonies were observed. Similarly, 
log 1.9 was attributed to lung plates where no colonies were observed. 
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Additional Methods 
Cloning of Ag85B as control protein for expression in N. benthamiana, Gateway cloning of 
TB-PIGS into mammalian expression vector, Western blotting to determine structure of 
PIGS, expression and detection of PIGS in CHO cells, flow cytometry methodology and 
maintenance of cell lines are described in supplementary material.   
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Figure Legends 
Figure 1: Design of TB-PIGS. (A) Linearized map of gene sequence for TB-PIGS. The 
main structural elements are indicated for both human and murine immunoglobulin-based 
scaffolds with the amino acid substitutions highlighted. (B) Diagrammatic representation 
of TB-PIGS ‘monomer’. Expected size of ~120K, not including any glycosylation. Diagram 
is not to scale; Ag85B portion is ~30K and truncated γ-chain is ~30K. (C) Diagrammatic 
representation of TB-PIGS ‘polymer’. Expected size of ~720K for hexamer, not including 
any glycosylation. There are potentially 6 glycosylation sites in one single-chain; 4 within 
Ag85B nucleotide sequence and 2 within truncated γ-chain. However, only two sites are 
predicted to be accessible for glycosylation to occur when protein is folded into 3D structure.    
 
Figure 2: Characterisation of assembly and size of TB-PIGS. In all cases 4-12% Bis-Tris 
gels with MOPS buffer were used. ~5-10 μg of protein was loaded per well.  
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(A) SDS-PAGE of purified human and murine TB-PIGS detected by Coomassie blue 
staining. Human IgG1, IgM and murine IgG2a are shown as controls. Panels i-ii are under 
non-reducing conditions, panels iii-iv are under reducing conditions. 
(B) Western blotting –Panels i and iv show detection using α-Ag85B antiserum under non-
reducing and reducing conditions respectively. Positive control is plant expressed Ag85B, 
negative control is an extract from a wild type N. benthamiana plant (W.T.). Samples are 
purified human (H) and murine (M) TB-PIGS; Panels ii and v show detection using α-human 
IgG1 antiserum under non-reducing and reducing conditions respectively. Positive control is 
commercial purified human IgG1; Panels iii and vi show detection using α-murine IgG2a 
antiserum under non-reducing and reducing conditions respectively. Positive control is 
commercial purified murine IgG2a; P indicates polymer; M indicates monomer and S 
indicates single-chain size of TB-PIGS. Molecular weight markers in K are indicated to the 
left of each gel. 
(C) Native PAGE of TB-PIGS. A 3-12% bis-tris gel in dark blue cathode and anode buffer 
was used. Molecular size markers are indicated on right-hand side of gel. P ~ polymer size; D 
~ dimer size and M ~ monomer size.  
(D) Size exclusion chromatography-ultraviolet spectrophotometry (SEC-UV). Bio Rad 
Standards include (from right to left) 1.35 kDa Vitamin B12 (0.5 mg), 17 kDa Horse 
Myoglobin (2.5 mg), 44 kDa Chicken Ovalbumin (5 mg), 158 kDa Bovine γ-globulin (5 mg) 
and 670 kDa Bovine Thyroglobulin (5 mg). A total volume of 20 µl was run for each sample. 
Human TB-PIGS:ΔXF was run at a sample concentration of 100 μg/ml and yielded four 
peaks. Murine TB-PIGS:ΔXF was run at a concentration of 100 μg/ml and yielded 2 peaks. 
Black numbers indicate the retention time of each peak.  
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Figure 3: Functional characterisation of TB-PIGS in vitro. (A) Complement-binding 
ELISA. ELISA plates were coated with 5 μg/ml human C1q. Positive control was ICMs 
(TBG65 and ACR). α-Mse γ1-HRP was used as detection antibody. Human TB-PIGS and 
HuIgG1 control were detected using α-Huγ1 antiserum. Murine TB-PIGS and MseIgG2a 
control were detected using α-Mseγ2a antiserum. (B) SPR analysis of avidity interaction 
between glyco-engineered human TB-PIGS and human CD32a. 1 μM of human TB-
PIGS:ΔXF or HuIgG1 were passed over the His-captured human CD32a. (C) Avidity 
analysis between glyco-engineered human TB-PIGS and human CD16a. 540 nM of 
human TB-PIGS:ΔXF or HuIgG1 were passed over the His-captured human CD16a.  
 
Figure 4: Confocal microscopy of THP1 cells with human TB-PIGS:ΔXF. Nuclei were 
stained with DAPI (blue), Ag85B was detected with rabbit α-Ag85B antiserum and goat α-
rabbit Ig-Alexa Fluor 488 (green), HuIgG γ-chain was detected with sheep α-HuIgG1 
antiserum and donkey α-sheep IgG-Alexa Fluor 633 (magenta). Superimposed images are 
shown (far right). In descending order, samples incubated with cells were; media only, 
isotype control (rabbit IgG-Alexa Fluor 488), HuIgG1 and human TB-PIGS:ΔXF. 
 
Figure 5: In vivo study of murine TB-PIGS in BALB/c mice. (A) Ag85B-specific-IgG 
responses. Three weeks after last immunisation, three mice were culled per group and serum 
was obtained. ELISA plates were coated with Ag85B and mean (±SEM) are depicted for total 
Ag85b specific IgG responses (top), IgG1 specific response (middle) and IgG2a specific 
response (bottom). (B) Polyfunctional CD4
+
 T-cell responses. Splenocytes were stimulated 
with Ag85B and stained for four different cytokines (IFN-γ, IL-2, IL-17 and TNF-α). 
Analysis of the percentage of positive CD4
+
 T-cells for each cytokine alone and in 
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combination was determined and represented in pie-charts (top). The total percentage of cells 
out of the events counted (before gating) are listed under the pie charts. The frequency of the 
antigen-specific cytokine producing cells are indicated in the graph (below). (C) 
Polyfunctional CD8
+
 T-cell responses. As for (B) but for CD8
+
 cells. (D) M. tuberculosis 
challenge and tissue colonisation. Extracts of lungs (left) and spleens (right) were plated out 
at three different dilutions per mouse, incubated for three weeks and the number of 
mycobacterial colonies counted. Mean (± SEM) are plotted per group. A one-way ANOVA 
with Tukey’s multiple comparisons test was performed to determine statistical significance. 
 
Figure 6: In vivo study of human TB-PIGS in transgenic CD64 mice. (A) α-Ag85B-
specific-IgG responses. Three weeks after last immunisation, three mice were culled per 
group and serum was obtained. ELISA plates were coated with Ag85B and mean (±SEM) are 
depicted for total IgG responses (top), IgG1 specific response (middle) and IgG2a specific 
response (bottom). (B) Cytokine response. Splenocytes were stimulated with Ag85B and 
levels of four different cytokines, in the supernatant, were determined by ELISA. A one-way 
ANOVA with Tukey’s multiple comparisons test was performed to determine statistical 
significance; * p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001. 
 
Figure 7: In vivo study of human TB-PIGS in transgenic CD64 mice. (A) Polyfunctional 
CD4
+
 T-cell responses. Splenocytes were stimulated with Ag85B and stained for four 
different cytokines (IFN-γ, IL-2, IL-17 and TNF-α). Analysis of the percentage of positive 
CD4
+
 T-cells for each cytokine alone and in combination was determined and represented in 
pie-charts (top). The total percentage of cells out of the events counted (before gating) are 
listed under the pie charts. The frequency of the antigen-specific cytokine producing cells are 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
indicated in the graph (below). (B) Polyfunctional CD8
+
 T-cell responses. As for (A) but for 
CD8
+
 cells. (C) Protective efficacy of human TB-PIGS against challenge with M. 
tuberculosis. Extracts of lungs (left) and spleens (right) were plated out at three different 
dilutions per mouse, incubated for three weeks and then the number of mycobacterial 
colonies counted. Mean (± SEM) are plotted per group. A one-way ANOVA with Tukey’s 
multiple comparisons test was performed to determine statistical significance. For 
simplification purposes, not all statistical significance has been indicated; * p<0.05, ** 
p<0.01, *** p<0.001 and **** p<0.0001.  
 
Supplementary Figure & Table Legends 
S1: SDS-PAGE of purified murine and human PIGS (without antigen) produced from 
CHO cells, under non-reducing and reducing conditions. A 4-12% Bis-Tris gel in MOPS 
buffer was used and ~20 μg of protein was loaded in all cases. Lane 1 was N. benthamiana 
produced human PIGS, lane 2 was N. benthamiana produced murine PIGS, lane 3 was CHO 
cell produced human PIGS under non-reducing conditions, lane 4 was CHO cell produced 
murine PIGS under non-reducing conditions, lane 5 was CHO cell produced human PIGS 
under reducing conditions and lane 6 was CHO cell produced murine PIGS under reducing 
conditions.  
 
S2: SPR kinetics and affinity analysis of TB-PIGS binding to FcγRs. (A) Human TB-
PIGS with human CD64. Eight different concentrations (240 nM down to 1.875 nM, 1:2 
dilutions) of CD64 were passed over the protein A-captured antibodies. 1:1 binding 
interaction model (black lines) was used for HuIgG1 and human TB-PIGS:ΔXF, whereas 
‘Heterogeneous antibody with aglycosylation’ model*1 (black lines) was used for wild-type 
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N. benthamiana produced human TB-PIGS and the curves were fitted to the experimental 
data (coloured lines). (B) Murine TB-PIGS with mouse CD64. Eight different 
concentrations (240 nM down to 1.875 nM, 1:2 dilutions) of CD64 were passed over the 
protein A-captured antibodies/PIGS. 1:1 binding interaction model (black lines) was used for 
all samples and the curves were fitted to the experimental data (coloured lines). (C) Steady-
state analysis of human TB-PIGS with human CD32a. Six different concentrations (4000 
nM to 125 nM in 2-fold dilutions) of CD32a were passed over the protein A-captured 
antibodies/PIGS. Affinity values were derived from steady states (using steady-state affinity 
analysis available in the evaluation software). (D) Human TB-PIGS with human CD16a. 
Five-six different concentrations of CD16a were passed over the protein A-captured 
antibodies/PIGS. Two-state binding interaction model (black lines) was used for all samples 
and the curves were fitted to the experimental data (coloured lines). 
 
*1
This model was created by Stelter et al. (manuscript in preparation) and was created based 
on heterogeneous ligand model, with calculates two separate sets of kinetic and affinity 
values. One set is defined and corresponds to kinetic/affinity values for aglycosylated heavy 
chains (as determined for a plant-produced aglycosylated human IgG1) and the second set 
calculates kinetic/affinity values for the glycosylated portion. 
 
S3: Flow cytometric analysis of human TB-PIGS:ΔXF with THP1 cells. This data is 
representative of two repeats. Pseudocolour plots for each sample are shown with percentage 
values for ‘negative’ population (left of each plot) and percentage values for ‘positive’ FITC 
population (right of each plot). Half-offset histogram for FITC fluorescence for each sample 
with their corresponding mean fluorescence intensity (MFI) values given on the right. THP1 
cells were incubated with (A) isotype FITC labelled MseIgG2a; (B) FITC labelled α-
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HuIgGγ1; (C) HuIgG1 and then FITC labelled α-HuIgGγ1; (D) heat aggregated HuIgG1 and 
then FITC labelled α-HuIgGγ1; (E) human TB-PIGS:ΔXF and then FITC labelled α-
HuIgGγ1. 
 
S4: Confocal microscopy of J774 cells with murine TB-PIGS:ΔXF. Nuclei were stained 
with DAPI (blue), actin filaments/cytoplasm stained with phalloidin (green; left), MseIgGγ2a 
stained with AlexaFluor633 (pink; right) and merged images (far right). In descending order, 
samples incubated with cells were; media only, secondary antibody only, MseIgG2a and 
murine TB-PIGS:ΔXF. 
 
S5: Flow cytometric analysis of murine TB-PIGS:ΔXF with J774 cells. This data is 
representative of two repeats. Pseudocolour plots for each sample are shown with percentage 
values for ‘negative’ population (left of each plot) and percentage values for ‘positive’ FITC 
population (right of each plot). Half-offset histogram for FITC fluorescence for each sample 
with their corresponding mean fluorescence intensity (MFI) values given on the right. J774 
cells were incubated with (A) isotype FITC labelled rat IgG1; (B) FITC labelled α-
MseIgGγ2a; (C) MseIgG2a and then FITC labelled α-MseIgGγ2a; (D) heat aggregated 
MseIgG2a and then FITC labelled α-MseIgGγ2a; (E) murine TB-PIGS:ΔXF and then FITC 
labelled α-MseIgGγ2a. 
 
Table S1: Yields for TB-PIGS produced in plants in mg of protein per kg of leaf mass. 
The yield of polymers, dimers and monomers was calculated based on the total yield of 
protein (mg/kg) and the percentages of each species calculated by native PAGE (NP) or size 
exclusion chromatography (SEC).  
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Table S2: Kinetic and Affinity values of TB-PIGS with FcγRs. Two sets of values were 
generated for wild-type plant produced TB-PIGS with CD64 – one for aglycosylated TB-
PIGS and one for glycosylated TB-PIGS present within the sample.  
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